CJC-1295 Bloodwork Guide: What Labs to Track (2026)
CJC-1295 bloodwork guide: track IGF-1, GH, fasting insulin, and thyroid markers with optimal ranges and testing timeline.
CJC-1295 Bloodwork Guide: What to Track and Why
CJC-1295 without DAC (Mod GRF 1-29) is a GHRH analog — it directly stimulates the pituitary to produce and release growth hormone. Unlike Ipamorelin (which works through the ghrelin receptor), CJC-1295 hits the GHRH receptor, and the two are frequently combined for synergistic GH release.
Because CJC-1295 stimulates the entire GH cascade from the top, its effects are broader: IGF-1, IGFBP-3, metabolic markers, and thyroid function can all shift. Bloodwork captures what subjective feel cannot.
The Testing Timeline
Baseline (before starting): Run all the tests below that match your goals, 1-2 weeks before your first dose. IGF-1, thyroid panel, and fasting insulin are the anchors.
Mid-protocol check (week 4-6): Retest IGF-1, fasting insulin, fasting glucose, and thyroid markers (TSH, free T3). This catches both GH axis activation and thyroid conversion changes.
Post-protocol (2-4 weeks after finishing): Retest everything you ran at baseline. This tells you what stuck and what bounced back.
What "full panel" means in this guide: IGF-1, IGFBP-3, fasting insulin, fasting glucose, HbA1c, TSH, free T3, free T4, CBC, CMP, and lipid panel as a minimum.
Biomarkers at a Glance
Click any bar to jump to the full breakdown.
Tier 1: Growth Hormone Axis
These biomarkers directly track CJC-1295's primary mechanism — stimulating GH secretion through the GHRH receptor on the pituitary.
Insulin-Like Growth Factor 1 (IGF-1)
What it measures: The downstream mediator of growth hormone. When GH reaches the liver, it stimulates IGF-1 production. IGF-1 has a longer half-life than GH, making it a stable, reliable marker of overall GH activity.
Why it matters for CJC-1295: This is your primary objective measure. CJC-1295 has been shown in clinical studies to increase IGF-1 levels 1.5-3x baseline in healthy adults. A meaningful rise (20-50% above baseline) confirms the GHRH pathway is being effectively stimulated.
Testing note: Draw IGF-1 fasted, in the morning. Consistency in timing improves comparability across tests.
Serum Growth Hormone (GH)
What it measures: Direct circulating growth hormone at the moment of the blood draw.
Why it matters: A stimulated GH test (drawn 15-30 minutes after CJC-1295 injection) can confirm acute pituitary GHRH receptor activation. However, GH's short half-life (~20 minutes) makes random draws meaningless.
Practical advice: Use stimulated GH testing only to confirm pituitary responsiveness early on. IGF-1 is the better tracking marker.
Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3)
What it measures: The primary carrier protein for IGF-1. About 75-80% of circulating IGF-1 is bound in a ternary complex with IGFBP-3 and ALS (acid-labile subunit).
Why it matters for CJC-1295: IGFBP-3 tells you whether IGF-1 elevation is physiologically balanced. If IGF-1 rises but IGFBP-3 stays flat, you have more "free" IGF-1 — which carries a different risk profile than bound IGF-1. Proportional increases in both suggest a healthy, regulated GH response.
Top CJC-1295 Vendors
Ranked by price, COA availability, and reputation
Tier 2: Metabolic Markers
Growth hormone directly affects glucose and insulin metabolism. CJC-1295, by amplifying GH output, can shift insulin sensitivity — this is expected physiology, not a unique side effect.
Fasting Insulin
What it measures: How much insulin your pancreas produces in a fasted state. Higher numbers suggest insulin resistance.
Why it matters for CJC-1295: GH is a counter-regulatory hormone to insulin. Increased GH from CJC-1295 can temporarily reduce insulin sensitivity. Fasting insulin catches this early, before glucose levels change.
High-performance target: Below 5 uIU/mL. Conventional "normal" goes up to 25, which is already metabolic dysfunction territory.
Fasting Glucose
What it measures: Blood sugar after an overnight fast.
Why it matters: If CJC-1295-driven GH increase is pushing insulin resistance, fasting glucose eventually rises. This is a lagging indicator — fasting insulin flags the issue first.
Hemoglobin A1c (HbA1c)
What it measures: Average blood sugar over the past 2-3 months.
Why it matters: HbA1c won't respond to a few weeks of slightly elevated glucose. But for longer CJC-1295 protocols, it captures cumulative metabolic impact.
Tier 3: Thyroid Markers
This is where CJC-1295 monitoring differs from Ipamorelin alone. Growth hormone increases the peripheral conversion of T4 (inactive thyroid hormone) to T3 (active thyroid hormone). If you have borderline thyroid function, elevated GH can unmask or exacerbate subclinical thyroid issues.
Thyroid Stimulating Hormone (TSH)
What it measures: How hard the pituitary is working to stimulate the thyroid. High TSH means the thyroid is underperforming. Low TSH means the thyroid is overactive (or getting extra T3 from GH-driven conversion).
Why it matters for CJC-1295: GH-driven T4-to-T3 conversion can lower TSH by increasing circulating T3, which feeds back to suppress TSH. If TSH drops during your protocol, check free T3 to confirm the mechanism.
Free T3 (Triiodothyronine)
What it measures: The active form of thyroid hormone. Free T3 drives metabolic rate, energy, and body temperature.
Why it matters for CJC-1295: If GH is accelerating T4-to-T3 conversion, free T3 will rise. A modest increase is often experienced as improved energy and metabolism. An excessive increase can cause hyperthyroid-like symptoms — anxiety, heart palpitations, heat intolerance.
Free T4 (Thyroxine)
What it measures: The storage/precursor form of thyroid hormone. The thyroid primarily produces T4, which gets converted to T3 in peripheral tissues.
Why it matters: If GH accelerates T4-to-T3 conversion, free T4 may slightly decrease while free T3 rises. This pattern — lower T4 with higher T3 — is a classic marker of enhanced peripheral conversion. It's not dangerous on its own but should be monitored.
Tier 4: Safety Panel
Standard safety monitoring to ensure CJC-1295 isn't causing unintended problems.
Complete Blood Count (CBC)
Checks red blood cells, white blood cells, and platelets. Standard baseline safety check. Growth hormone can modestly affect hematologic markers over time.
Comprehensive Metabolic Panel (CMP)
Covers liver enzymes (ALT, AST), kidney function (BUN, creatinine), electrolytes, and protein levels.
Standard lab ranges go up to 40 U/L for ALT, but optimal is below 25.
Lipid Panel
Total cholesterol, LDL, HDL, and triglycerides. Growth hormone influences lipid metabolism — generally improving the profile by reducing visceral fat and boosting HDL.
How to Order Labs
You don't necessarily need a doctor's visit for every test:
- Direct-to-consumer labs: HealthLabs.com lets you order bloodwork without a prescription or insurance. Order online, walk into any of 4,500+ LabCorp or Quest draw sites, and get results in 1-2 business days.
- Your primary care doctor: If you have a good relationship with your doctor, ask them to add these to your regular bloodwork. IGF-1, thyroid panel, fasting insulin, and lipid panels are commonly ordered.
- IGFBP-3: May require specialty ordering at some labs. Available through most functional medicine practitioners.
Budget-conscious approach: If you can only afford a few tests, prioritize in this order:
- IGF-1 ($30-50) — the single most important marker for CJC-1295
- TSH + free T3 ($30-50 together) — thyroid monitoring unique to GH protocols
- Fasting insulin + fasting glucose ($20-40 together) — metabolic safety
- CBC + CMP ($20-40 bundled) — general safety
Putting It All Together: Sample Protocol
Week -1 (Baseline): Run IGF-1, IGFBP-3, fasting insulin, fasting glucose, HbA1c, TSH, free T3, free T4, CBC, CMP, and lipid panel. This is your "before" snapshot.
Week 1-4 (CJC-1295 protocol): Focus on subjective tracking — sleep quality, recovery speed, energy, body composition. Journal it. Watch for any signs of thyroid shifts (unusual anxiety, temperature sensitivity, resting heart rate changes).
Week 4-5 (Mid-protocol): Retest IGF-1, fasting insulin, fasting glucose, TSH, and free T3. If IGF-1 rose meaningfully and thyroid markers are in range, the protocol is working safely. If TSH dropped significantly with elevated free T3, discuss with a healthcare provider.
Week 8-12 (Post-protocol): Retest everything you ran at baseline. Compare each marker. Document what changed and by how much. Thyroid markers should normalize within 2-4 weeks of stopping.
What to do with results: If IGF-1 and IGFBP-3 rose proportionally, metabolic markers held steady, and thyroid stayed in range, the protocol was effective and safe. If thyroid shifted significantly or fasting insulin climbed, those are signals to adjust the approach.
Related Reading
-
CJC-1295 Dosing Guide — protocols, timing, and cycles
-
CJC-1295 Reconstitution Guide — step-by-step mixing and dilution charts
-
Ipamorelin Bloodwork Guide — the classic pairing partner
-
BPC-157 Bloodwork Guide — healing peptide biomarker profile
-
GHK-Cu Bloodwork Guide — copper peptide tissue repair tracking
-
BPC-157 Dosing Guide — commonly stacked healing peptide
References
- Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. PubMed:16352683
- Ionescu, M., et al. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797. PubMed:17018654
- Jette, L., et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052-3058. PubMed:15817669
- Sam, S., et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477. PMC2787983
This guide is for educational and informational purposes only. It is not medical advice. CJC-1295 is sold as a research compound and is not FDA-approved for human use. The biomarker ranges described here reflect optimization targets used in functional and sports medicine — they are not diagnostic criteria. Lab results should be interpreted by a qualified healthcare provider in the context of your full medical history. The Peptide Catalog is not responsible for medical decisions made based on information presented here. HealthLabs.com links are affiliate links — we may earn a commission at no additional cost to you.